Suppr超能文献

阿巴卡韦不影响抑制 HIV 患者循环中炎症或凝血生物标志物的水平:一项随机临床试验。

Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial.

机构信息

National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia.

出版信息

AIDS. 2010 Nov 13;24(17):2657-63. doi: 10.1097/QAD.0b013e32833f147f.

Abstract

OBJECTIVE

The Simplification of antiretroviral therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine trial (STEAL) study randomized HIV participants to switch existing nucleoside reverse transcriptase inhibitors (NRTI) to either abacavir/lamivudine (ABC/3TC; n = 179) or tenofovir/emtricitabine (TDF/FTC; n = 178). An increased risk in cardiovascular disease (CVD) was reported (hazard ratio 7.7, P = 0.048) in ABC/3TC recipients compared with TDF/FTC in the STEAL study. The impact of ABC/3TC treatment on a range of CVD and inflammatory biomarkers was explored.

DESIGN AND METHODS

Biomarkers were assessed at 0, 12, 24, and 48 weeks to examine: inflammation - high sensitive C-reactive protein, amyloid-P, amyloid-A, interleukin 6, interleukin 10, interferon α, and macrophage migration inhibitory factor; coagulation - D-dimer and fibrinogen; platelet function - soluble P-selectin; endothelial function - vascular cell adhesion molecule 1 and intercellular adhesion molecule 1; renal function - cystatin C. The primary endpoint was the difference between arms for mean change from baseline to week 12. Secondary analyses were differences between groups for mean change from baseline to weeks 24 and 48, time-weighted change from baseline to week 48, and changes to week 12 stratified by Framingham CVD risk score at baseline.

RESULTS

Sera were available from 330 (92%) of 357 participants. At baseline, all biomarkers were similar between treatment arms and when stratified for baseline NRTI exposure. There were no significant differences between treatment arms in the mean change from baseline to week 12 for any biomarkers. No consistent between-group differences were seen in the secondary analyses that could suggest one pathophysiological pathway.

CONCLUSION

A thorough examination of selected biomarkers associated with cardiovascular morbidity and mortality did not reveal associations with the use of ABC/3TC relative to use of TDF/FTC.

摘要

目的

简化抗逆转录病毒治疗与替诺福韦-恩曲他滨或阿巴卡韦-拉米夫定试验(STEAL)研究将现有的核苷逆转录酶抑制剂(NRTI)转换为阿巴卡韦/拉米夫定(ABC/3TC;n = 179)或替诺福韦/恩曲他滨(TDF/FTC;n = 178)。STEAL 研究报告称,与 TDF/FTC 相比,ABC/3TC 组接受治疗的 HIV 患者心血管疾病(CVD)风险增加(风险比 7.7,P = 0.048)。研究探索了 ABC/3TC 治疗对一系列 CVD 和炎症生物标志物的影响。

设计和方法

在 0、12、24 和 48 周时评估生物标志物,以检查:炎症 - 高敏 C 反应蛋白、淀粉样蛋白-P、淀粉样蛋白-A、白细胞介素 6、白细胞介素 10、干扰素-α和巨噬细胞迁移抑制因子;凝血 - D-二聚体和纤维蛋白原;血小板功能 - 可溶性 P-选择素;内皮功能 - 血管细胞黏附分子 1 和细胞间黏附分子 1;肾功能 - 胱抑素 C。主要终点是从基线到第 12 周的手臂间平均变化差异。次要分析是组间从基线到第 24 周和第 48 周的平均变化差异、从基线到第 48 周的时间加权变化差异以及根据基线Framingham CVD 风险评分进行分层的第 12 周变化差异。

结果

357 名参与者中有 330 名(92%)提供了血清。在基线时,治疗组之间的所有生物标志物均相似,并且在根据基线 NRTI 暴露进行分层时也相似。在从基线到第 12 周的平均变化方面,各治疗组之间没有显著差异。在次要分析中,也没有看到任何一致的组间差异,这些差异可能表明存在一种病理生理途径。

结论

对与心血管发病率和死亡率相关的选定生物标志物进行了全面检查,但未发现与使用 ABC/3TC 相关的生物标志物与使用 TDF/FTC 相关的差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验